Overview

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of cyclophosphamide plus dexamethasone combined with rituximab or bortezomib regimens in newly diagnosed Waldenström macroglobulinemia patients.
Phase:
Phase 4
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital
Treatments:
BB 1101
Bortezomib
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Rituximab